Austin’s Terapio Corp. and Abilene’s Receptor Logic get $3M from Texas Emerging Technology Fund

June 19, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Austin Business Journal -- An Abilene company creating new antibodies and an Austin group working to counteract a chemotherapy side effect are the latest to receive investments from the Texas Emerging Technology Fund.

Twitter
LinkedIn
Facebook
Email
Print